MDACC Study No:2011-0307 ( NCT No: NCT01339052)
Title:A Phase II Study of BKM120 for Patients with Recurrent Glioblastoma and
Activated PI3K Pathway
Principal Investigator:W K Alfred Yung
Treatment Agent:BKM120
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if BKM120 (buparlisib) can
help to control glioblastoma and/or gliosarcoma. Researchers also want to
learn more about how much study drug is in different areas of the body at
different time points. The safety of this drug will also be studied.

BKM120 is designed to block a protein that is important to the growth and
division of cancer cells, which may cause the cells to die.
Hide details for General InformationGeneral Information

Disease Group:Brain; CNS
Phase of Study:Phase II
Treatment Agents:BKM120
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Dana-Farber/Partners CancerCare.Inc
Novartis Pharmaceuticals.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:W K Alfred Yung
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults